Despite Price Tags, Economics Driving M&A Will Endure In ’08, Biotech Investors Say
This article was originally published in The Pink Sheet Daily
Recession indicators are giving health care investors the jitters but fund managers at BIO CEO & Investor Conference remain confident on biotech.
You may also be interested in...
The biotech has not received “any definitive offers.”
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.
Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.